Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02421601 · ClinicalTrials.gov registry record · Phase 3
A Study of SI-6603 in Patients With Lumbar Disc Herniation
A Phase 3 study, sponsored by Seikagaku Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,011
- Enrollment target
NCT02421601 is a Phase 3 study that has completed, run by Seikagaku Corporation. The registered enrollment target is 1,011 participants.
The verdict
NCT02421601, a Phase 3 study, has completed, sponsored by Seikagaku Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,011 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of SI-6603(Condoliase) in patients with lumbar disc herniation.
Interventions
- DRUG Condoliase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,011 participants |
| Start Date | 2015-03 |
| Est. Completion | 2018-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02421601
The ClinicalTrials.gov registry entry for NCT02421601 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,011 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seikagaku Corporation, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Condoliase is the first listed.
NCT02421601 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02421601 about?
NCT02421601 is a clinical study titled "A Study of SI-6603 in Patients With Lumbar Disc Herniation". The purpose of this study is to evaluate the safety and efficacy of SI-6603(Condoliase) in patients with lumbar disc herniation.
What is the current status of trial NCT02421601?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,011 participants. The study started on 2015-03. Estimated completion is 2018-02.
What interventions are being tested in trial NCT02421601?
The interventions under investigation include: Condoliase (DRUG).
Who is sponsoring clinical trial NCT02421601?
This trial is sponsored by Seikagaku Corporation, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.